

# The Journal of Rheumatology

VOLUME 43: NO. 3

jrheum.org

MARCH 2016

## Editorials

- Is There a Future for Interleukin 17 Blocking Agents in Rheumatoid Arthritis?** *P. Durez* ..... 465
- Spondyloarthritis. Clinical Versus Imaging Assessment: And the Winner Is?** *D. Wendling, S. Aubry, C. Prati* ..... 468
- Do Biologic-treated Psoriatic Arthritis Patients with Spondylitis Respond Differently with or without Concomitant Methotrexate from Patients without Spondylitis?** *P.J. Mease* ..... 471

## Articles

- GREM1 Is a Key Regulator of Synovocyte Hyperplasia and Invasiveness** *E.J. Han, S.A. Yoo, G.M. Kim, et al* ... 474
- The Framingham Score and the Systematic Coronary Risk Evaluation at Low Cutoff Values Are Useful Surrogate Markers of High-risk Subclinical Atherosclerosis in Patients with RA**  
*P.H. Dessein, A. Corrales, R. Lopez-Mejias, et al* ..... 486
- Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active RA: Results from a Randomized Phase II Study**  
*W. Tlustochowicz, P. Rahman, B. Seriole, et al* ..... 495
- Efficacy and Safety of Baricitinib in Japanese Patients with Active RA Receiving Background MTX Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study** *Y. Tanaka, K. Emoto, Z. Cai, et al* ..... 504
- The Rate of Adherence to Antiarthritis Medications and Associated Factors among Patients with Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis**  
*A. Scheiman-Elazary, L. Duan, C. Shourt, et al* ..... 512
- Characteristics Predicting TB Risk under TNF- $\alpha$  Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence**  
*B. Kisacik, O.N. Pamuk, A.M. Onat, et al* ..... 524
- Development of System-level Performance Measures for Evaluation of Models of Care for Inflammatory Arthritis in Canada** *C.E. Barber, D.A. Marshall, D.P. Mosher, et al, and the Arthritis Alliance of Canada Performance Measurement Development Panel* ..... 530

- Genetic Variants That Are Associated with Neuropsychiatric SLE** *R.C. Ho, H. Ong, C. Thiaghu, Y. Lu, C.S. Ho, M.W. Zhang* ..... 541
- Mycophenolate Mofetil in Nonrenal Manifestations of SLE: An Observational Cohort Study**  
*K. Tselios, D.D. Gladman, J. Su, M.B. Urowitz* ..... 552
- Clinical Features, Morbidity, and Risk Factors of Intestinal Pseudo-obstruction in SLE: A Retrospective Case-control Study** *L. Zhang, D. Xu, H. Yang, et al* ..... 559
- Predictors of Incident Seizure in SLE**  
*X.Y. Huang, L.S. Magder, M. Petri* ..... 565
- Venous and Arterial Thrombotic Events in SLE**  
*A. Hinojosa-Azaola, J. Romero-Diaz, A.G. Vargas-Ruiz, et al* ..... 576
- Monocytic Angiotensin and Endothelin Receptor Imbalance Modulate Secretion of the Profibrotic Chemokine Ligand 18**  
*J. Rademacher, A. Kill, K. Mattat, et al* ..... 587
- Assessment, Definition, and Classification of Lower Limb Ulcers in SSc: A Challenge for the Rheumatologist**  
*J. Blagojevic, G. Piemonte, L. Benelli, et al* ..... 592
- Quantitative Alterations of Capillary Diameter Have a Predictive Value for Development of the Capillaroscopic SSc Pattern**  
*A.C. Trombetta, V. Smith, C. Pizzorni, et al* ..... 599
- Nonsteroidal Antiinflammatory Drugs for AxSpa: A Cochrane Review**  
*F.P. Kroon, L.R. van der Burg, S. Ramiro, et al* ..... 607
- Comparison of Clinical Examination versus Whole-body MRI of Enthesitis in Patients with Early AxSpA during 3 Years of Continuous Etanercept Treatment**  
*C.E. Althoff, J. Sieper, I.H. Song, et al* ..... 618
- Risk of Psychiatric Disorders following AS: A Nationwide Population-based Retrospective Cohort Study**  
*C.C. Shen, L.Y. Hu, A.C. Yang, B.I. Kuo, Y.Y. Chiang, S.J. Tsai* ..... 625
- Does Concomitant MTX with Adalimumab Influence Treatment Outcomes in Patients with PsA? Data from a Large Observational Study**  
*F. Behrens, M. Koehm, U. Arndt, et al* ..... 632

 Free online via JRheum Full Release option

Contents continued on page xx

---

**Incremental Costs for Psoriasis and Psoriatic Arthritis in a Population-based Cohort in Southern Sweden: Is It All Psoriasis-attributable Morbidity?**

*S. Löfvendahl, I.F. Petersson, E. Theander, Å. Svensson, C. Zhou, K. Steen Carlsson . . . . . 640*

**Severe Intracranial Involvement in Giant Cell Arteritis: 5 Cases and Literature Review**

*R.S. Alsolaimani, S.V. Bhavsar, N.A. Khalidi, et al . . . . . 648*

**High Kellgren-Lawrence Grade and Bone Marrow Lesions Predict Worsening Rates of Radiographic Joint Space Narrowing; The SEKOIA Study**

*M.H. Edwards, C. Parsons, O. Bruyère, et al, and the SEKOIA Study Group . . . . . 657*

**Improved Function and Reduced Pain after Swimming and Cycling Training in Patients with OA**

*M. Alkatan, J.R. Baker, D.R. Machin, et al. . . . . 666*

**Images in Rheumatology**

**Sacroiliitis-like Changes in 2 Patients with Spina Bifida**

*J. Chan, I. Sari, N. Haroon. . . . . 673*

**Subcutaneous Sarcoidosis Mimicking Cellulitis**

*K.Y. Won, S.Y. Park, S.H. Lee . . . . . 674*

**Correspondence**

**Systemic Sclerosis and Outcome in Intensive Care Unit: Do Not Close the Door, Open the Right Protocol**

*P. Faverio, A. Pesci, A.M. Esquinas . . . . . 676*

**Reply** *F. Pène, Y. Allanore, L. Mouthon . . . . . 677*

**Assessment of Serum Uric Acid in Young Male Patients with Ankylosing Spondylitis**

*T. Dogan, M. Agilli . . . . . 678*

**Reply** *K.Y. Kang, J.H. Ju . . . . . 678*

**Letter**

**Genetic Markers in a Medieval Case of Ankylosing Spondylitis**

*I. Martín Laza, M. Hervella, C. De-La-Rúa . . . . . 679*

**Corrections**

**Specific Antinuclear Antibody Level Changes after B Cell Depletion Therapy in Systemic Sclerosis Are Associated with Improvement of Skin Thickening**

*C. Bonroy, V. Smith, E. Deschepper, F. De Keyser, K. Devreese . . . . . 681*

**Risk of Venous Thromboembolism after Total Knee Arthroplasty in Patients with Rheumatoid Arthritis**

*M. Izumi, K. Migita, M. Nakamura, Y. Jiuchi, T. Sakai, T. Yamaguchi, et al. . . . . 681*

**Meetings in Rheumatology . . . . . x**